KCNQ1 Gene (KV7.1)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KCNQ1 (KV7.1)</th>
</tr>
<tr>
<td class="label">
Symbol</td>
<td>KCNQ1</td>
</tr>
<tr>
<td class="label">
Full Name</td>
<td>Potassium Voltage-Gated Channel Subfamily Q Member 1</td>
</tr>
<tr>
<td class="label">
Synonyms</td>
<td>Kv7.1, KCNA1, LQT1</td>
</tr>
<tr>
<td class="label">
Chromosomal Location</td>
<td>11p15.5</td>
</tr>
<tr>
<td class="label">
NCBI Gene ID</td>
<td>3785</td>
</tr>
<tr>
<td class="label">
OMIM ID</td>
<td>607542</td>
</tr>
<tr>
<td class="label">
Ensembl ID</td>
<td>ENSG00000143338</td>
</tr>
<tr>
<td class="label">
UniProt ID</td>
<td>P51787</td>
</tr>
<tr>
<td class="label">
Protein Length</td>
<td>676 amino acids</td>
</tr>
<tr>
<td class="label">
Molecular Weight</td>
<td>~75 kDa</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Beta-blockers</td>
<td>First-line LQT1 treatment</td>
</tr>
<tr>
<td class="label">Potassium channel activators</td>
<td>Flavinoids (e.g., nicorandil)</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-KCNQ1 delivery</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/cardiac" style="color:#ef9a9a">Cardiac</a>, <a href=
...KCNQ1 Gene (KV7.1)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KCNQ1 (KV7.1)</th>
</tr>
<tr>
<td class="label">
Symbol</td>
<td>KCNQ1</td>
</tr>
<tr>
<td class="label">
Full Name</td>
<td>Potassium Voltage-Gated Channel Subfamily Q Member 1</td>
</tr>
<tr>
<td class="label">
Synonyms</td>
<td>Kv7.1, KCNA1, LQT1</td>
</tr>
<tr>
<td class="label">
Chromosomal Location</td>
<td>11p15.5</td>
</tr>
<tr>
<td class="label">
NCBI Gene ID</td>
<td>3785</td>
</tr>
<tr>
<td class="label">
OMIM ID</td>
<td>607542</td>
</tr>
<tr>
<td class="label">
Ensembl ID</td>
<td>ENSG00000143338</td>
</tr>
<tr>
<td class="label">
UniProt ID</td>
<td>P51787</td>
</tr>
<tr>
<td class="label">
Protein Length</td>
<td>676 amino acids</td>
</tr>
<tr>
<td class="label">
Molecular Weight</td>
<td>~75 kDa</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Beta-blockers</td>
<td>First-line LQT1 treatment</td>
</tr>
<tr>
<td class="label">Potassium channel activators</td>
<td>Flavinoids (e.g., nicorandil)</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-KCNQ1 delivery</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/cardiac" style="color:#ef9a9a">Cardiac</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/ovarian-cancer" style="color:#ef9a9a">Ovarian Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">149 edges</a></td>
</tr>
</table>
Overview
Kcnq1 (Kv7.1) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Kcnq1 (Kv7.1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
KCNQ1 (Potassium Voltage-Gated Channel Subfamily Q Member 1), also known as Kv7.1, is a gene encoding a voltage-gated potassium channel subunit. KCNQ1 forms homomeric or heteromeric channels that generate the slowly activating delayed rectifier potassium current (IKs). These channels are critical for cardiac repolarization and epithelial electrolyte transport.
Gene Overview
Gene Structure
The KCNQ1 gene consists of 19 exons spanning approximately 19 kb of genomic DNA on chromosome 11p15.5. This region is within the imprinted domain associated with Beckwith-Wiedemann syndrome. The gene produces multiple transcript variants through alternative splicing.
Protein Structure
KCNQ1 is a voltage-gated potassium channel with distinctive domains:
- S1-S6 transmembrane segments: Core voltage-sensing and pore-forming structure
- Voltage sensor domain (S1-S4): Detects membrane potential changes
- Pore domain (S5-S6): Forms the potassium-selective ion conduction pathway
- N-terminal domain: Interacts with KCNE subunits and regulatory proteins
- C-terminal domain: Contains assembly signals and regulatory sites
The channel assembles as a tetramer, with each subunit contributing to the functional channel.
Normal Function
KCNQ1 channels perform essential functions in various tissues:
Cardiac Function
In cardiac myocytes, KCNQ1:
- Generates the slowly activating delayed rectifier current (IKs)
- Contributes to action potential repolarization
- Prevents early afterdepolarizations
- Modulates QT interval duration
Epithelial Transport
In epithelial cells, KCNQ1:
- Regulates salt transport across epithelia
- Controls gastric acid secretion
- Modulates intestinal chloride secretion
- Affects renal potassium handling
Neuronal Function
In [neurons](/entities/neurons), KCNQ1 (as Kv7.1):
- Contributes to neuronal excitability
- Regulates firing patterns
- Modulates neurotransmitter release
- May influence cognitive function
Expression Pattern
KCNQ1 exhibits broad expression:
- Heart: High expression in atrial and ventricular myocytes
- Inner ear: Stria vascularis for potassium recycling
- Kidney: Tubular epithelial cells
- Gastric mucosa: Parietal cells
- Brain: Lower expression in various regions
- Cerebral [cortex](/brain-regions/cortex)
- [Hippocampus](/brain-regions/hippocampus)
- Cerebellum
Disease Associations
Long QT Syndrome Type 1 (LQT1)
KCNQ1 mutations cause the most common form of long QT syndrome:
- Inheritance: Autosomal dominant (most) or recessive (rare)
- Clinical features:
- Prolonged QT interval on ECG
- Syncope, often triggered by exercise
- Torsades de pointes
- Risk of sudden cardiac death
- Triggers: Swimming, exercise, sudden loud noises
Jervell and Lange-Nielsen Syndrome
Homozygous/compound heterozygous KCNQ1 mutations:
- Congenital deafness
- Long QT syndrome
- Severe cardiac phenotype
Atrial Fibrillation
Gain-of-function mutations:
- Short QT phenotype
- Increased atrial excitability
Epilepsy
Rare associations with seizure disorders:
- Altered neuronal excitability
- May modify seizure susceptibility
Alzheimer's Disease
Potential roles:
- Neuronal potassium homeostasis
- Possible interaction with [Aβ](/proteins/amyloid-beta) signaling
Parkinson's Disease
- May affect dopaminergic neuron function
- Altered expression in PD models
Therapeutic Implications
Animal Models
Kcnq1 Knockout Mice
- Embryonic lethality in complete knockout
- Heterozygotes show prolonged QT
- Inner ear defects
Transgenic Models
- Cardiac-specific overexpression
- Point mutation knock-in models
Research Directions
- Developing gene therapy approaches
- Understanding genotype-phenotype correlations
- Identifying pharmacological chaperones
- Exploring modifier genes
Overview
Kcnq1 (Kv7.1) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Kcnq1 (Kv7.1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
<sup>[1]</sup> Wang J, et al. (2010). "KCNQ1: Structure, function, and regulation." Journal of Molecular and Cellular Cardiology. 49(2): 203-213.
<sup>[2]</sup> Jespersen T, et al. (2005). "The KCNQ1 potassium channel: from gene to physiological function." Physiology. 20: 408-416.
<sup>[3]</sup> Hedley PL, et al. (2009). "The genetic basis of long QT and short QT syndromes." Heart Rhythm. 6(8): 1139-1149.
<sup>[4]</sup> Neyroud N, et al. (1997). "A novel mutation in the potassium channel gene KCNQ1 causes long QT syndrome." Nature Genetics. 15(2): 186-189.
<sup>[5]</sup> Brown DA, et al. (2017). "Neuronal KV7 (KCNQ) channels and their modulators as therapeutic targets." Neuropharmacology. 113: 620-633.
See Also
- [Potassium Channels](/mechanisms/potassium-channel-dysfunction)
- [Voltage-Gated Ion Channels](/mechanisms/ion-channel-dysfunction)
- KCNQ Family
- Long QT Syndrome
- Cardiac Channelopathies
- [Ion Channelopathies](/mechanisms/ion-channel-dysfunction)
External Links
- [KCNQ1 Gene - NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/3785)
- [KCNQ1 Protein - UniProt](https://www.uniprot.org/uniprot/P51787)
- [KCNQ1 - GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=KCNQ1)
Pathway Diagram
The following diagram shows the key molecular relationships involving KCNQ1 (KV7.1) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)